Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Hematol ; 11(6): 233-239, 2022 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-36632577

RESUMEN

Bone involvement is a rare extranodal manifestation in patients with malignant lymphoproliferative diseases and has also been noted as a rare event in patients with Waldenstrom macroglobulinemia (WM). However, the actual prevalence has not been previously reported. We describe an unusual case of a patient with WM who presented with lower back pain and focal bone lesions at initial diagnosis. Magnetic resonance imaging (MRI) revealed multiple vertebral fractures. Positron emission tomography (PET) detected only nodal changes without pathological skeletal-related metabolic activity. Lymph node and bone marrow biopsies combined with an immunoglobulin M (IgM) M component revealed the diagnosis of WM. A next-generation sequencing (NGS) analysis using a targeted lymphoma panel of 59 recurrently mutated genes in lymphoid neoplasms showed mutations in the MYD88 and CD79B genes. After treatment with rituximab and bendamustine, the patient achieved a partial remission and pain relief. After 3 years of stable disease, a spontaneous subcapital fracture at the base of the femoral neck and new vertebral compression fractures occurred. Whole-body low-dose computed tomography (WB-LDCT) and bone density (dual energy X-ray absorptiometry (DEXA)) scan revealed marked osteopenia. After insertion of a hip prosthesis, examination of the removed hip showed infiltration of clonal lymphoplasmacytic cells. Our case confirms that one must be aware that bone involvement in patients with WM can occur as a rare manifestation. Interestingly, the MYD88/CD79B-mutated (MCD) genotype in diffuse large B-cell lymphoma is characterized by extranodal involvement and may also be involved in the pathogenesis of skeletal-related disease in the present case. As a follow-up to this unusual case, we have carried out an analysis based on the Danish Lymphoma Registry (LYFO) covering the entire national population in the period 2000 - 2020. The registry study included a cohort of 2,459 patients with WM and lymphoplasmacytic lymphoma. Our data revealed that primary bone involvement at diagnosis occurs in 1.75% of adults with WM. To the best of our knowledge, this is the first report of the prevalence of skeletal-related disease in a large nationwide cohort and defines bone involvement as an exceedingly rare event in WM.

2.
Blood Cancer J ; 10(5): 57, 2020 05 14.
Artículo en Inglés | MEDLINE | ID: mdl-32409671

RESUMEN

Sézary syndrome (SS) is a heterogeneous leukemic subtype of cutaneous T-cell lymphoma (CTCL) with generalized erythroderma, lymphadenopathy, and a poor prognosis. Advanced disease is invariably associated with severe immune dysregulation and the majority of patients die from infectious complications caused by microorganisms such as, Staphylococcus aureus, rather than from the lymphoma per se. Here, we examined if staphylococcal enterotoxins (SE) may shape the phenotype of malignant SS cells, including expression of the regulatory T-cell-associated marker FOXP3. Our studies with primary and cultured malignant cells show that SE induce expression of FOXP3 in malignant cells when exposed to nonmalignant cells. Mutations in the MHC class II binding domain of SE-A (SEA) largely block the effect indicating that the response relies at least in part on the MHC class II-mediated antigen presentation. Transwell experiments show that the effect is induced by soluble factors, partly blocked by anti-IL-2 antibody, and depends on STAT5 activation in malignant cells. Collectively, these findings show that SE stimulate nonmalignant cells to induce FOXP3 expression in malignant cells. Thus, differences in exposure to environmental factors, such as bacterial toxins may explain the heterogeneous FOXP3 expression in malignant cells in SS.


Asunto(s)
Enterotoxinas/inmunología , Factores de Transcripción Forkhead/genética , Síndrome de Sézary/inmunología , Neoplasias Cutáneas/inmunología , Infecciones Estafilocócicas/inmunología , Staphylococcus aureus/inmunología , Línea Celular Tumoral , Factores de Transcripción Forkhead/inmunología , Humanos , Síndrome de Sézary/complicaciones , Síndrome de Sézary/genética , Neoplasias Cutáneas/complicaciones , Neoplasias Cutáneas/genética , Infecciones Estafilocócicas/complicaciones , Infecciones Estafilocócicas/genética , Linfocitos T/inmunología , Linfocitos T/metabolismo , Células Tumorales Cultivadas , Regulación hacia Arriba
3.
Blood ; 134(13): 1072-1083, 2019 09 26.
Artículo en Inglés | MEDLINE | ID: mdl-31331920

RESUMEN

It has been proposed that CD4 T-cell responses to Staphylococcus aureus (SA) can inadvertently enhance neoplastic progression in models of skin cancer and cutaneous T-cell lymphoma (CTCL). In this prospective study, we explored the effect of transient antibiotic treatment on tumor cells and disease activity in 8 patients with advanced-stage CTCL. All patients experienced significant decrease in clinical symptoms in response to aggressive, transient antibiotic treatment. In some patients, clinical improvements lasted for more than 8 months. In 6 of 8 patients, a malignant T-cell clone could be identified in lesional skin, and a significant decrease in the fraction of malignant T cells was observed following antibiotics but an otherwise unchanged treatment regimen. Immunohistochemistry, global messenger RNA expression, and cell-signaling pathway analysis indicated that transient aggressive antibiotic therapy was associated with decreased expression of interleukin-2 high-affinity receptors (CD25), STAT3 signaling, and cell proliferation in lesional skin. In conclusion, this study provides novel evidence suggesting that aggressive antibiotic treatment inhibits malignant T cells in lesional skin. Thus, we provide a novel rationale for treatment of SA in advanced CTCL.


Asunto(s)
Antibacterianos/uso terapéutico , Linfoma Cutáneo de Células T/tratamiento farmacológico , Neoplasias Cutáneas/tratamiento farmacológico , Anciano , Proliferación Celular/efectos de los fármacos , Femenino , Humanos , Linfoma Cutáneo de Células T/metabolismo , Linfoma Cutáneo de Células T/patología , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Factor de Transcripción STAT3/metabolismo , Transducción de Señal/efectos de los fármacos , Neoplasias Cutáneas/metabolismo , Neoplasias Cutáneas/patología , Linfocitos T/efectos de los fármacos , Linfocitos T/metabolismo , Linfocitos T/patología
4.
Blood ; 131(7): 759-770, 2018 02 15.
Artículo en Inglés | MEDLINE | ID: mdl-29208599

RESUMEN

Mycosis fungoides (MF) is the most frequent form of cutaneous T-cell lymphoma. The disease often takes an indolent course, but in approximately one-third of the patients, the disease progresses to an aggressive malignancy with a poor prognosis. At the time of diagnosis, it is impossible to predict which patients develop severe disease and are in need of aggressive treatment. Accordingly, we investigated the prognostic potential of microRNAs (miRNAs) at the time of diagnosis in MF. Using a quantitative reverse transcription polymerase chain reaction platform, we analyzed miRNA expression in diagnostic skin biopsies from 154 Danish patients with early-stage MF. The patients were subdivided into a discovery cohort (n = 82) and an independent validation cohort (n = 72). The miRNA classifier was built using a LASSO (least absolute shrinkage and selection operator) Cox regression to predict progression-free survival (PFS). We developed a 3-miRNA classifier, based on miR-106b-5p, miR-148a-3p, and miR-338-3p, which successfully separated patients into high-risk and low-risk groups of disease progression. PFS was significantly different between these groups in both the discovery cohort and the validation cohort. The classifier was stronger than existing clinical prognostic factors and remained a strong independent prognostic tool after stratification and adjustment for these factors. Importantly, patients in the high-risk group had a significantly reduced overall survival. The 3-miRNA classifier is an effective tool to predict disease progression of early-stage MF at the time of diagnosis. The classifier adds significant prognostic value to existing clinical prognostic factors and may facilitate more individualized treatment of these patients.


Asunto(s)
MicroARNs/genética , Micosis Fungoide/diagnóstico , Micosis Fungoide/genética , Neoplasias Cutáneas/diagnóstico , Neoplasias Cutáneas/genética , Transcriptoma , Biomarcadores de Tumor/genética , Dinamarca/epidemiología , Progresión de la Enfermedad , Regulación Neoplásica de la Expresión Génica , Humanos , Micosis Fungoide/patología , Micosis Fungoide/terapia , Estadificación de Neoplasias , Pronóstico , Supervivencia sin Progresión , Neoplasias Cutáneas/patología , Neoplasias Cutáneas/terapia
5.
Wound Repair Regen ; 25(6): 984-993, 2017 11.
Artículo en Inglés | MEDLINE | ID: mdl-29316016

RESUMEN

We explored use of the suction-blister wound model in the assessment of not only epidermal regeneration but also pain, the microvascular response and bacteriology. The effects of topical zinc sulfate were studied to articulate the methodologies in this double-blind trial. One epidermal suction blister (10 mm) was induced on each buttock in 30 healthy volunteers (15 females:15 males) and deroofed on day 0. The wounds were randomized to daily treatment with 1.4% zinc sulfate shower gel (n = 20), placebo (n = 20) or control (n = 20). Digital photography coupled with planimetry, transepidermal water loss (TEWL) measurement and optical coherence tomography (OCT) was benchmarked to the gold standard of histology of 60 full-thickness wound biopsies on day 4. Pain increased after application of the shower gels. Microvessel density, determined from OCT images, increased from day 0 to day 2 in the three groups but increased more with the placebo than with the zinc shower gel (p = 0.003) or the control treatment (p = 0.002) and correlated (rS = 0.313, p = 0.015) with the inflammatory response on day 4, as determined by histology. Coagulase-negative staphylococci were more common in wounds compared with skin (p = 0.002) and was reduced (p = 0.030) with zinc sulfate treatment. Planimetric analysis of digital wound images was not biased (p = 0.234) compared with histology, and TEWL measurements showed no correlation (rS = 0.052, p = 0.691) with epithelialization. Neoepidermal formation, determined by histology, did not differ (p = 0.290) among the groups. Zinc sulfate reduced (p = 0.031) the release of lactate dehydrogenase from cultured gel-treated keratinocytes isolated from the blister roofs. Therefore, combination of the standardized suction-blister wound model with noninvasive planimetry and OCT is a useful tool for assessing wound therapies. Zinc sulfate transiently dampened inflammation and reduced bacterial growth.


Asunto(s)
Vesícula/patología , Epidermis/patología , Microvasos/patología , Repitelización , Adulto , Astringentes/farmacología , Astringentes/uso terapéutico , Benchmarking , Vesícula/diagnóstico por imagen , Vesícula/tratamiento farmacológico , Vesícula/microbiología , Membrana Celular/efectos de los fármacos , Membrana Celular/metabolismo , Células Cultivadas , Método Doble Ciego , Epidermis/lesiones , Epidermis/microbiología , Femenino , Voluntarios Sanos , Humanos , Queratinocitos/efectos de los fármacos , Queratinocitos/metabolismo , L-Lactato Deshidrogenasa/efectos de los fármacos , L-Lactato Deshidrogenasa/metabolismo , Masculino , Persona de Mediana Edad , Dolor/fisiopatología , Staphylococcus/aislamiento & purificación , Succión , Tomografía de Coherencia Óptica , Adulto Joven , Sulfato de Zinc/farmacología , Sulfato de Zinc/uso terapéutico
6.
Acta Derm Venereol ; 96(7): 917-921, 2016 11 02.
Artículo en Inglés | MEDLINE | ID: mdl-27117439

RESUMEN

Interaction between tumour survival tactics and anti-tumour immune response is a major determinant for cancer growth. Regulatory T cells (T-regs) contribute to tumour immune escape, but their role in basal cell carcinoma (BCC) is not understood. The fraction of T-regs among T cells was analysed by immunohistochemistry followed by automated image analysis in facial BCC, peritumoural skin and normal, buttock skin. Quantitative real-time PCR (qRT-PCR) was performed for Foxp3 and cytokines involved in T-reg attraction and T-cell activation. T-regs comprised 45% of CD4-cells surrounding BCC. Foxp3 was highly expressed in BCC, but absent in buttock skin. Unexpectedly, expression of Foxp3 was increased in peritumoural skin, with the FoxP3/CD3 fractions exceeding those of BCC (p = 0.0065). Transforming growth factor (TGF)-ß and T-reg chemokine expression was increased in BCC and peritumoural skin, but not in buttock skin, with expression levels correlating with Foxp3. T-regs are abundantly present both in BCC and in peritumoural skin, mediating an immunosuppressed microenvironment permissive for skin cancer


Asunto(s)
Carcinoma Basocelular/inmunología , Neoplasias Cutáneas/inmunología , Linfocitos T Reguladores/inmunología , Biopsia , Carcinoma Basocelular/metabolismo , Citocinas/metabolismo , Factores de Transcripción Forkhead/metabolismo , Humanos , Inmunohistoquímica , Activación de Linfocitos , Reacción en Cadena en Tiempo Real de la Polimerasa , Neoplasias Cutáneas/metabolismo
7.
J Acquir Immune Defic Syndr ; 66(4): 349-57, 2014 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-24784764

RESUMEN

BACKGROUND: HIV-infected immunological nonresponders fail to immune reconstitute despite optimal treatment. We hypothesized that regulatory T cells (Tregs) are involved in immunological reconstitution. Tregs and Treg subpopulations were measured in blood and Foxp3 cells in lymphoid tissue, and the impact of Tregs on immunological reconstitution was determined. METHODS: HIV-infected individuals on combination antiretroviral therapy for a minimum of 2 years were included. The study population included 14 immunological nonresponders (INR; CD4 T-cell count <200 cells/µL), 33 intermediate responders (CD4 T-cell count 200-500 cells/µL), 30 responders (CD4 T-cell count >500 cells/µL), and 34 healthy controls. Tregs, Treg subpopulations, and intracellular staining for interleukin 10 in peripheral blood were measured using flow cytometry. Foxp3 cells in lymphoid tissue were evaluated using immunolabeling. The CD4 T-cell count was determined at inclusion and after 1 year of follow-up. RESULTS: INR displayed high percentage of Tregs and activated Tregs in peripheral blood accompanied by a high percentage of Tregs expressing interleukin 10, whereas numbers of Foxp3 cells in lymphoid tissue were low. In contrast, responders resembled healthy controls. Finally, in INR, high level of Tregs in blood and Foxp3 cells in lymphoid tissue were associated with higher level of immunological reconstitution after 1 year of follow-up. CONCLUSIONS: In conclusion, altered distribution of Tregs was found in INR. Interestingly, high level of Tregs predicted higher level of immunological reconstitution suggesting a role for Tregs in immunological reconstitution.


Asunto(s)
Fármacos Anti-VIH/uso terapéutico , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/inmunología , Tejido Linfoide/citología , Linfocitos T Reguladores/fisiología , Adulto , Anciano , Recuento de Linfocito CD4 , Estudios de Casos y Controles , Femenino , Factores de Transcripción Forkhead/genética , Factores de Transcripción Forkhead/metabolismo , Regulación de la Expresión Génica/inmunología , Humanos , Interleucina-10/genética , Interleucina-10/metabolismo , Masculino , Persona de Mediana Edad
8.
J Acquir Immune Defic Syndr ; 65(1): 10-8, 2014 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-23995946

RESUMEN

BACKGROUND: HIV-infected controllers control viral replication and maintain normal CD4 T cell counts. Long-term nonprogressors (LTNPs) also maintain normal CD4 T cell counts but have ongoing viral replication. We hypothesized that immunoregulatory mechanisms are involved in preserved CD4 T cell counts in controllers and in LTNPs. METHODS: Twenty HIV-infected viremic controllers, 5 elite controllers (ECs), and 14 LTNPs were included in this cross-sectional study. For comparison, 25 progressors and 34 healthy controls were included. Regulatory T cells (Tregs), Treg subpopulations, CD161+Th17 cells, and CD3+CD8+CD161(high)Tc17 cells in peripheral blood were measured using flow cytometry. Tregs in lymphoid tissue were determined in tonsil biopsies and evaluated using immunolabeling. The production of transforming growth factor beta (TGF-ß), interleukin (IL)-10, and IL-17 upon stimulation with phytohemagglutinin in peripheral blood was determined by Luminex. RESULTS: All groups of HIV-infected patients displayed similar percentages of Tregs in both peripheral blood and lymphoid tissue. However, a larger percentage of Tregs in ECs and LTNPs were activated compared with that in controls, progressors, and viremic controllers. Further, ECs as the only group of HIV-infected patients, displayed elevated percentages of CD161+Th17 cells, preserved CD3+CD8+CD161(high)Tc17 cells, and preserved IL-10 production. CONCLUSIONS: Overall, Treg percentage was similar in both blood and lymphoid tissue in all groups of patients and controls. However, both ECs and LTNPs displayed a large proportion of activated Tregs suggesting immunoregulatory mechanisms to be involved in preserving CD4 T cell counts in HIV-infected nonprogressors.


Asunto(s)
Recuento de Linfocito CD4 , Infecciones por VIH/inmunología , Sobrevivientes de VIH a Largo Plazo , Linfocitos T Reguladores/fisiología , Adulto , Complejo CD3/inmunología , Linfocitos T CD8-positivos/inmunología , Linfocitos T CD8-positivos/fisiología , Estudios de Casos y Controles , Estudios Transversales , Femenino , Citometría de Flujo , Humanos , Interleucina-10/sangre , Interleucina-17/sangre , Subgrupos Linfocitarios/inmunología , Subgrupos Linfocitarios/fisiología , Masculino , Persona de Mediana Edad , Subfamilia B de Receptores Similares a Lectina de Células NK/inmunología , Linfocitos T Reguladores/inmunología , Células Th17/inmunología , Células Th17/fisiología , Factor de Crecimiento Transformador beta/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...